Spero Therapeutics, Inc.

( )
SPRO PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
JNJJohnson & Johnson 0.15%163.470.7%$1332.86m
LLYEli Lilly & Co. 0.74%324.001.1%$1075.83m
ABBVAbbVie, Inc. 0.86%139.491.9%$859.47m
PFEPfizer Inc. 0.09%44.150.9%$798.34m
BMYBristol-Myers Squibb Co. -0.03%70.521.0%$772.56m
MRKMerck & Co., Inc. 0.32%87.840.7%$712.72m
AZNAstraZeneca Plc 1.60%56.441.0%$393.70m
ALNYAlnylam Pharmaceuticals, Inc. 0.00%196.798.2%$217.39m
GSKGSK Plc 1.89%30.800.3%$213.46m
NVSNovartis AG 1.66%77.940.2%$205.00m
GBTGlobal Blood Therapeutics, Inc. 0.00%68.485.4%$191.16m
IDXXIDEXX Laboratories, Inc. 1.12%340.463.9%$186.35m
ATXIAvenue Therapeutics, Inc. 29.80%14.940.0%$180.82m
HZNPHorizon Therapeutics Plc 0.00%64.265.4%$173.65m
SRPTSarepta Therapeutics, Inc. 0.00%109.9412.4%$136.73m

Company Profile

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.